Bioprocessing & Manufacturing



With new vaccine formulations and technology platforms, vaccine developers need to have the right processes in place to manufacture them during clinical trials and at commercial scale. Use this opportunity to meet with the manufacture and bioprocessing leads who need services for all of the latest manufacturing challenges, from formulating and manufacturing adjuvants, mRNA platforms, VLPs and viral vectors, to technology transfer and continuous manufacturing.






Bioprocess & Manufacture, Wednesday 4 April 2018

Vaccine Bioprocessing

Parrish Galliher
Bioprocess & Manufacture

Practical solutions enabling rapid production of viral based therapies

Dr Ahd Hamidi
Bioprocess & Manufacture

Latest advancements in production process intensification to support demand for affordable vaccines

  • Use of fixed-bed bioreactors
  • Development of microfacilities
Dr Pascal Longchamp
Bioprocess & Manufacture

Long range production platform for pharmaceuticals: Application to CRM197


Networking coffee break

Dr Don Gerson
Bioprocess & Manufacture

What can we learn from mAB bioprocessing to vaccines to make more vaccines? From R&D to full scale manufacturing and worldwide distribution

  • The transition from lab to manufacturing and large-scale production of low cost vaccines globally
Dr Wilfried Bakker
Bioprocess & Manufacture

Bridging the Global Health Gap – Viral and bacterial vaccine development at Intravacc

Vaccine Production and Delivery Systems

Dr Max Søgaard
Bioprocess & Manufacture

ExpreS2 – an insect cell based vaccine production system suitable for difficult-to-express proteins

Elizabeth Joseph
Bioprocess & Manufacture

Analytical characterization of aluminum adsorbed vaccines: Stability indicating methods for product release

  • What general guidance is there on release and stability test methods for aluminum adsorbed vaccines?  
  • Understanding of the antigen stability following adsorption
  • Reviewing potential release tests and proposing a panel of stability indicating tests for aluminum adsorbed vaccines

Networking Lunch & Poster Session

Darin Zehrung
Bioprocess & Manufacture

Review of the current alternative vaccine delivery methods and how their effectiveness is assessed

  • The advantages and progression of up taking alternative delivery systems and packaging
  • The logistical challenges to consider for developing countries
  • How to make new technologies applicable and build a stronger business case to be used
  • Total system effectiveness: Cost modelling of delivery systems
Michael A. Schrader
Bioprocess & Manufacture

Creating the next generation of vaccines and immunotherapies by mimicking an infection to enhance the immune response

  • Illustrating how the delivery of sustained release vaccine depots via microneedle patch improves immunogenicity
  • Logistical conquest in easy administration, shelf life stability and only minutes of wear time
  • Current progress with an in-house influenza vaccine and partnered programs to advance formulation for optimal patient uptake
Dr Ahmad Ghoniem
Bioprocess & Manufacture

A patch and a laser = vaccination without a cold chain?

Dr Victor Ayala
Bioprocess & Manufacture

Accelerating vaccine production using a non-viral enabling technology for cell engineering

  • Discuss Phase I, fully-scalable technology that allows efficient, cost-effective evaluation of vaccine candidates
  • Learn about the role media has on antigen folding, expression and glycosylation for transfection
  • Review customized purification techniques and characterization assays to overcome variability

Networking coffee break

Bioprocess needs for the developed & developing world

Peter Khoury
Bioprocess & Manufacture

Vaccine self-sufficiency and responding to pandemic outbreaks from small to large scale

  • Understanding in securing strains, safety,  regulatory hurdles and manufacturing hurdles
  • Considering the logistics of distribution
Ranjeet Patil
Bioprocess & Manufacture

A new paradigm for vaccine process development: solving challenges through supplier-manufacturer collaborations

Dr Yan-ping Yang
Bioprocess & Manufacture

Continuous Process for Vaccine Manufacturing: Challenges and opportunities

  • Experiences & lessons learned from the industry on continuous processing
  • Disposable technology & continuous technology: a powerful combination
  • Rapid technology advancement for key enablers to support continuous processing
  • FDA Fully on Board with the Concept of continuous processing

Chair’s closing remarks and close of congress day 2


Networking Drinks & Party

last published: 02/Apr/18 21:25

Bioprocess & Manufacture, Thursday 5 April 2018

Enabling Technologies from Discovery to Market

Prof Fikri Avci
Bioprocess & Manufacture

Understanding how vaccines elicit immune responses

Dr Seth Thomas
Bioprocess & Manufacture

Enabling translation of vaccine discovery into clinical candidates in academia

Dr Fiona Lin
Bioprocess & Manufacture

Designing vaccines focusing on critical quality attributes and analytical strategies


Networking coffee break

Dr Viliam Pavliak
Bioprocess & Manufacture

Developing vaccines for developing countries – A case study on Typhoid conjugate vaccine


Networking Lunch & Poster Session


Dr Angela Shen

Report on U.S. vaccine development and innovation including the current landscape, existing challenges, and drivers and levers to incentivize development

  • A combined effort from HHS, NIH, CDC, FDA, BARDA to promote innovation in the development of vaccines that minimize the burden of infectious disease
  • What is the optimal process to determine which vaccines would be beneficial to public health and how information on such vaccines is disseminated to key stakeholders
  • Identifying whether obstacles exist that inhibit the development of beneficial vaccines
  • Recommendations on how best to promote and incentivize vaccine innovation and development
Dr Jeffrey Stoddard

Zoster vaccine recombinant, adjuvanted: A journey from research to approval

  • Non-live, recombinant vaccine to help prevent herpes zoster (shingles), combining glycoprotein E with an adjuvant system, AS01
  • Sharing positive results from Phase III revaccination study 
Dr Walter A Orenstein

With polio eradication succeeding, should measles eradication come next?

  • Changing the perception from polio: Focusing on measles elimination to build our overall immunization program
  • Using a “diagonal” approach when dealing with highly contagious preventable diseases like measles
  • Surveillance -  a weakness in our system?
  • Cost of controlling outbreaks and the consequences
Dr Paul Offit

Vaccine hesitancy: How to respond to the media to advance better health

  • Challenges to communicating science through the opaque prism of the media
  • How certain cultural biases can influence the perception of science 

3:40 Chair closing remarks and end of congress

last published: 02/Apr/18 21:25


Get Involved At World Vaccine Congress Washington


To Sponsor Or Exhibit

Marc Rhys-Evans
+44 20 7827 5945




To Register

Tayyab Abbasi
+44 20 7092 1210




Press Relations

Karina Kusova
+44 20 7092 1071